Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform
Hangzhou Diagens Biotechnology Co., Ltd. announced a filing for an initial public offering (IPO) to...
Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...
GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection
GlaxoSmithKline plc (GSK, NYSE: GSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT) for USD 58.00...
Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
Alteogen Inc. (KOSDAQ: 196170) announced an exclusive license agreement with Tesaro, a GSK subsidiary, granting worldwide...
Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...
Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...
Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon‑2...
Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Eyebright Medical Technology Co., Ltd (SHA: 688050) announced plans to acquire a controlling stake of...
AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification
AstraZeneca plc (AZ, NASDAQ: AZN) announced it will delist its American Depositary Shares (ADS) and debt...
Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate
Beijing Merson Pharmaceutical Co., Ltd. announced that its Bemejing (timolol maleate gel) has obtained China’s...
Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology...
Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real‑world study of OT-703 (fluocinonide...
AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
AIM Vaccine Co., Ltd (HKG: 6660) announced that China’s National Medical Products Administration (NMPA) has...
Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
Shionogi Co., Ltd announced it will invest USD 2.1 billion to increase its stake in ViiV Healthcare...
Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Grand Pharmaceutical Group Limited (HKG: 0512) announced it has filed TLX591-CDx (Illuccix, gallium Ga 68...
D3 Bio’s KRAS Programs Advance: FDA Clears Phase I G12D Inhibitor D3S‑003 and Phase II G12C‑ERK Combo
D3 Bio announced FDA clearance for two clinical programs: a Phase I first‑in‑human study for D3S‑003,...
Aidea’s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China’s National Medical Products Administration (NMPA)...
Blue Sail’s Lithonic IVL System Wins CE Mark for Coronary Calcified Lesions
Blue Sail Medical Co., Ltd (SHE: 002382) announced that its Lithonic coronary intravascular shockwave therapy...
Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections
Shionogi Co., Ltd announced that China’s National Medical Products Administration (NMPA) has granted marketing approval...
Chiesi’s Raxone Begins LHON Treatment in China, First World‑Approved Therapy
Chiesi Group announced that the first patients have initiated treatment with Raxone (idebenone 150 mg) at...